

- Sisay, S., Lopez-Lozano, L., Mickunas, M., Quiroga-Fernández, A., **Palace, J.**, Warnes, G., . . . Meier, U. C. (2017). Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.. *J Neuroimmunol*, 306, 40-45. doi:[10.1016/j.jneuroim.2017.02.017](https://doi.org/10.1016/j.jneuroim.2017.02.017)
- Waters, P., Reindl, M., Saiz, A., Schanda, K., Tuller, F., Kral, V., . . . Marignier, R. (2016). Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.. *Journal of neurology, neurosurgery, and psychiatry*, 87(9), 1005-1015.
- Jurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., . . . **Palace, J.** (2017). Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.. *Brain*, 140(3), 617-627. doi:[10.1093/brain/aww350](https://doi.org/10.1093/brain/aww350)
- Jurynczyk, M., Tackley, G., Kong, Y., Geraldes, R., Matthews, L., Woodhall, M., . . . **Palace, J.** (2016). Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. *Journal of Neurology, Neurosurgery and Psychiatry*. doi:[10.1136/jnnp-2016-314005](https://doi.org/10.1136/jnnp-2016-314005)
- Tackley, G., Vecchio, D., Hamid, S., Jurynczyk, M., Kong, Y., Gore, R., . . . **Palace, J.** (2016). Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.. *J Neurol Neurosurg Psychiatry*. doi:[10.1136/jnnp-2016-314991](https://doi.org/10.1136/jnnp-2016-314991)
- Geraldes, R., Esiri, M. M., DeLuca, G. C., & **Palace, J.** (2016). Age-related small vessel disease: A potential contributor to neurodegeneration in multiple sclerosis.. *Brain Pathol*. doi:[10.1111/bpa.12460](https://doi.org/10.1111/bpa.12460)
- Kong, Y., Okoruwa, H., Revis, J., Tackley, G., Leite, M. I., Lee, M., . . . **Palace, J.** (2016). Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.. *Journal of the neurological sciences*, 368, 84-88.
- Vermersch, P., Berger, T., Gold, R., Lukas, C., Rovira, A., Meesen, B., . . . **Palace, J.**, Trojano, M. (2016). The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 22(2 Suppl), 18-33.
- Hardy, T. A., Reddel, S. W., Barnett, M. H., **Palace, J.**, Lucchinetti, C. F., & Weinschenker, B. G. (2016). Atypical inflammatory demyelinating syndromes of the CNS.. *The Lancet. Neurology*, 15(9), 967-981.
- Seixas, D., **Palace, J.**, & Tracey, I. (2016). Chronic pain disrupts the reward circuitry in multiple sclerosis.. *The European journal of neuroscience*.
- Rodríguez Cruz, P. M., Belaya, K., Basiri, K., Sedghi, M., Farrugia, M. E., Holton, J. L., . . . **Palace, J.**, Beeson, D. (2016). Clinical features of the myasthenic syndrome arising from mutations in GMPPB.. *Journal of neurology, neurosurgery, and psychiatry*.
- Tackley, G., O'Brien, F., Rocha, J., Woodhall, M., Waters, P., Chandratre, S., . . . **Palace, J.** (2016). Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. *Multiple Sclerosis and Related Disorders*, 7, 21-25. doi:[10.1016/j.msard.2016.02.014](https://doi.org/10.1016/j.msard.2016.02.014)
- Waters, P., **Palace, J.**, Leite, M. I., Woodhall, M., & Vincent, A. (n.d.). Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. *Journal of Neurology, Neurosurgery and Psychiatry*. doi:[10.1136/jnnp-2015-312601](https://doi.org/10.1136/jnnp-2015-312601)
- Huda, S., Cavey, A., Izat, A., Mattison, P., Boggild, M., & **Palace, J.** (2016). Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.. *Journal of the neurological sciences*, 362, 66-68. doi:[10.1016/j.jns.2016.01.011](https://doi.org/10.1016/j.jns.2016.01.011)
- Kitley, J., & **Palace, J.** (2016). Therapeutic options in neuromyelitis optica spectrum disorders.. *Expert review of neurotherapeutics*, 16(3), 319-329. doi:[10.1586/14737175.2016.1150178](https://doi.org/10.1586/14737175.2016.1150178)
- Chaouch, A., Porcelli, V., Cox, D., Edvardson, S., Scarcia, P., De Grassi, A., . . . Lochmüller, H. (2014). Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission.. *Journal of neuromuscular diseases*, 1(1), 75-90.
- Filippi, M., Rocca, M. A., Ciccarelli, O., De Stefano, N., Evangelou, N., Kappos, L., . . . Barkhof, F. (2016). MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.. *The Lancet. Neurology*, 15(3), 292-303. doi:[10.1016/s1474-4422\(15\)00393-2](https://doi.org/10.1016/s1474-4422(15)00393-2)
- Allen, N. M., Hacoheh, Y., **Palace, J.**, Beeson, D., Vincent, A., & Jungbluth, H. (2016). Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome.. *Neurology*.
- Finlayson, S., Morrow, J. M., Rodríguez Cruz, P. M., Sinclair, C. D., Fischmann, A., Thornton, J. S., . . . **Palace, J.** (2016). Muscle MRI in congenital myasthenic syndromes.. *Muscle & nerve*. doi:[10.1002/mus.25035](https://doi.org/10.1002/mus.25035)
- Nour, M. M., Nakashima, I., Coutinho, E., Woodhall, M., Sousa, F., Revis, J., . . . Leite, M. I. (2016). Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.. *Neurology*, 86(1), 79-87. doi:[10.1212/wnl.0000000000002208](https://doi.org/10.1212/wnl.0000000000002208)

- Binks, S., Vincent, A., & **Palace, J.** (2015). Myasthenia gravis: a clinical-immunological update.. *Journal of neurology*.
- Piccolo, L., Woodhall, M., Tackley, G., Juryńczyk, M., Kong, Y., Domingos, J., . . . **Palace, J.** (2015). Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.. *Journal of neurology*.
- Logan, C. V., Cossins, J., Rodríguez Cruz, P. M., Parry, D. A., Maxwell, S., Martínez-Martínez, P., . . . Beeson, D. (2015). Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII α 1 Chain.. *American journal of human genetics*, 97(6), 878-885. doi:[10.1016/j.ajhg.2015.10.017](https://doi.org/10.1016/j.ajhg.2015.10.017)
- Juryńczyk, M., Weinshenker, B., Akman-Demir, G., Asgari, N., Barnes, D., Boggild, M., . . . **Palace, J.** (2016). Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.. *Journal of neurology*, 263(1), 140-149. doi:[10.1007/s00415-015-7952-8](https://doi.org/10.1007/s00415-015-7952-8)
- Matthews, L., Kolind, S., Brazier, A., Leite, M. I., Brooks, J., Traboulsee, A., . . . **Palace, J.** (2015). Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. *PLOS ONE*, 10(9). doi:[10.1371/journal.pone.0137715](https://doi.org/10.1371/journal.pone.0137715)
- Rodríguez Cruz, P. M., **Palace, J.**, Ramjattan, H., Jayawant, S., Robb, S. A., & Beeson, D. (2015). Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.. *Neurology*.
- Schanda, K., Waters, P., Holzer, H., Aboulenein-Djamshidian, F., Leite, M. I., **Palace, J.**, . . . Reindl, M. (2015). Antibodies to aquaporin-1 are not present in neuromyelitis optica. *Neurology: Neuroimmunology & Neuroinflammation*, 2(6), e160. doi:[10.1212/NXI.0000000000000160](https://doi.org/10.1212/NXI.0000000000000160)
- Kitley, J., Woodhall, M., Leite, M. I., **Palace, J.**, Vincent, A., & Waters, P. (2015). Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO.. *Neurology® Neuroimmunology & Neuroinflammation*, 2(4), e121. doi:[10.1212/nxi.0000000000000121](https://doi.org/10.1212/nxi.0000000000000121)
- Melamed, E., Levy, M., Waters, P. J., Sato, D. K., Bennett, J. L., John, G. R., . . . Zamvil, S. (2015). Update on biomarkers in neuromyelitis optica.. *Neurology® Neuroimmunology & Neuroinflammation*, 2(4), e134. doi:[10.1212/nxi.0000000000000134](https://doi.org/10.1212/nxi.0000000000000134)
- Belaya, K., Rodríguez Cruz, P. M., Liu, W. W., Maxwell, S., McGowan, S., Farrugia, M. E., . . . Beeson, D. (2015). Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.. *Brain : a journal of neurology*. doi:[10.1093/brain/awv185](https://doi.org/10.1093/brain/awv185)
- Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., . . . Vincent, A. (2015). MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.. *Neurology® Neuroimmunology & Neuroinflammation*, 2(3), e89. doi:[10.1212/nxi.0000000000000089](https://doi.org/10.1212/nxi.0000000000000089)
- Kremer, S., Renard, F., Achard, S., Lana-Peixoto, M. A., **Palace, J.**, Asgari, N., . . . O'Connor, K. (2015). Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.. *JAMA neurology*, 72(7), 815-822. doi:[10.1001/jamaneurol.2015.0248](https://doi.org/10.1001/jamaneurol.2015.0248)
- Murchison, A., Kitley, J., Leite, M. I., Küker, W., & **Palace, J.** (2015). Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease.. *Journal of the neurological sciences*, 355(1-2), 49-53. doi:[10.1016/j.jns.2015.05.011](https://doi.org/10.1016/j.jns.2015.05.011)
- Palace, J.** (2015). Placebo studies should not be undertaken in NMO--Yes.. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 21(6), 689-691. doi:[10.1177/1352458515579446](https://doi.org/10.1177/1352458515579446)
- Palace, J.** (2015). What is Seronegative NMO?. *MULTIPLE SCLEROSIS JOURNAL*, 21(6), 801-802. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354258600031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=4fd6f7d59a501f9b8bac2be37914c43e
- Pandit, L., Asgari, N., Apiwattanakul, M., **Palace, J.**, Paul, F., Leite, M. I., . . . Chitnis, T. (2015). Demographic and clinical features of neuromyelitis optica: A review.. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 21(7), 845-853. doi:[10.1177/1352458515572406](https://doi.org/10.1177/1352458515572406)
- Rodríguez Cruz, P. M., Al-Hajjar, M., Huda, S., Jacobson, L., Woodhall, M., Jayawant, S., . . . **Palace, J.** (2015). Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.. *JAMA neurology*, 72(6), 642-649. doi:[10.1001/jamaneurol.2015.0203](https://doi.org/10.1001/jamaneurol.2015.0203)
- Weinshenker, B. G., Barron, G., Behne, J. M., Bennett, J. L., Chin, P. S., Cree, B. A., . . . Yeaman, M. R. (2015). Challenges and opportunities in designing clinical trials for neuromyelitis optica.. *Neurology*, 84(17), 1805-1815. doi:[10.1212/wnl.0000000000001520](https://doi.org/10.1212/wnl.0000000000001520)
- Palace, J.**, Duddy, M., Bregenzer, T., Lawton, M., Zhu, F., Boggild, M., . . . Dobson, C. (2015). Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.. *The Lancet. Neurology*, 14(5), 497-505. doi:[10.1016/s1474-4422\(15\)00018-6](https://doi.org/10.1016/s1474-4422(15)00018-6)
- Hacohen, Y., Absoud, M., Deiva, K., Hemingway, C., Nytrova, P., Woodhall, M., . . . Waters, P. (2015). Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.. *Neurology® Neuroimmunology & Neuroinflammation*, 2(2), e81. doi:[10.1212/nxi.0000000000000081](https://doi.org/10.1212/nxi.0000000000000081)